Physician profile
Ali Hemacha
NPI 1225000870
$36,939.61
in general payments reported to CMS, 2019-2025
38 companies · $6,720 in 2025
The $6,720 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,890 · 2020: $543 · 2021: $1,708 · 2022: $2,800 · 2023: $2,656 · 2024: $21K · 2025: $6,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $9,389 · Travel and Lodging: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,780.00 |
| Food and Beverage | $9,389.29 |
| Travel and Lodging | $830.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $21,600.64 | 2024-2025 | Voquezna |
| Abbvie INC. | $2,709.54 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,470.74 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,689.28 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,554.50 | 2019-2025 | Tremfya, Stelara, Remicade |
| Ironwood Pharmaceuticals, INC | $1,066.85 | 2019-2025 | Linzess |
| Allergan, INC. | $998.47 | 2019-2020 | |
| Celgene Corporation | $997.91 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $770.91 | 2019-2025 | |
| Ardelyx, INC. | $298.45 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $287.63 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $254.91 | 2020-2023 | Rebyota |
| Qol Medical, LLC | $248.02 | 2023-2024 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $213.84 | 2023-2025 | Ocaliva |
| Celltrion USA INC. | $212.04 | 2024-2025 | Vegzelma, Zymfentra |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $194.76 | 2022-2025 | Sutab, Suflave |
| Regeneron Healthcare Solutions, INC. | $186.48 | 2022-2024 | Dupixent |
| Genzyme Corporation | $161.16 | 2022-2024 | |
| Pfizer INC. | $150.12 | 2019-2025 | |
| Exact Sciences Corporation | $126.34 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $90.98 | 2024-2025 | |
| Evoke Pharma, INC. | $89.31 | 2023-2025 | Gimoti |
| Redhill Biopharma INC. | $87.73 | 2021-2022 | |
| Alfasigma USA, INC. | $72.62 | 2020 | |
| Novo Nordisk INC | $62.89 | 2025 | Wegovy |
| Olympus America INC. | $55.38 | 2020-2023 | Single Use Electrosurgical Snare Sd-400, Endoclot Phs |
| Lilly USA, LLC | $54.07 | 2025 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.63 | 2023-2024 | Cyltezo |
| Boston Scientific Corporation | $38.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.97 | 2022 | |
| Shire North American Group INC | $21.73 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $19.21 | 2019 | |
| Masimo Corporation | $17.00 | 2021 | |
| Mindray Ds USA, INC. | $16.51 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2022 | |
| Merck Sharp & Dohme LLC | $14.82 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $13.17 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Hemacha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.